Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Looking for a particular Axcella employee's phone or email?
Axcella Questions
The Axcella annual revenue was $13.6 million in 2026.
Ralph Yamamoto is the Senior Director of Analytical Science and Technology of Axcella.
10 people are employed at Axcella.
Axcella is based in Cambridge, Massachusetts.
The NAICS codes for Axcella are [32, 32541, 325, 3254].
The SIC codes for Axcella are [28, 283].
Top Axcella Employees
-
Ralph Yamamoto
Senior Director of Analytical Science and Technology at Axcella
Melrose Park, IL, US35+ -
Shirley Williams
Director Data Management at Axcella
United States11 -
Rui Rosa
Manager laboratory and facilities at Axcella
Waltham, MA, US13 -
Steven Z
Associate Manager, Accounting at Axcella
Boston, MA, US1 -
Matthew Russell
Principal Scientist at Axcella
Cambridge, MA, US1
Related Companies
